Login to Your Account



BIOSIMILARS

As Nesp patent nears expiration, Kirin sets up new biosimilar firm

By Haky Moon
Staff Writer

Wednesday, February 8, 2017

HONG KONG – It is not surprising that Tokyo-based Kyowa Hakko Kirin Co. Ltd. wants to hold on to Nesp (darbepoetin alfa), an erythropoiesis-stimulating agent used as a treatment for improving renal anemia, when the patent expires in 2019.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription